Over a quarter ago |
On The Fly
| ShowHide Related Items >><< - 02/03/23
- Tenax Therapeutics announces pricing of approximately $15.6M public offering
- 02/01/23
- Tenax receives NOA from USPTO for patent for levosimendan in PH-HFpEF
- 01/04/23
- Tenax Therapeutics announces 1-for-20 reverse stock split
- 10/10/22
- Tenax Therapeutics announces presentation of data from study of levosimendan
- 02/01/23
- Evelo Biosciences provides clinical, business updates
- 11/21/22
- ImmunoGen names Daniel Char as Senior Vice President and Chief Legal Officer
- 11/15/22
- Evelo Biosciences announces publication of peer-reviewed article
- 08/11/22
- Evelo Biosciences announces CEO succession plan
- 10/13/22
- Erytech Pharma receives noncompliance notification from Nasdaq
- 08/24/22
- Erytech Pharma SA trading resumes
- 08/24/22
- Erytech Pharma no longer seeking approval for Graspa following FDA feedback
- 08/24/22
- Erytech Pharma SA trading halted, news pending
- 01/13/23
- Equillium announces abstract accepted for oral presentation at ASTCT, CIBMTR
- 12/23/22
- Equillium, Metracrine mutually agree to terminate merger agreement
- 12/16/22
- Equillium, Biocon initiate itolizumab study
- 12/08/22
- BML takes 15% stake in Metracrine, plans to vote against merger
ADIL Adial Pharmaceuticals - 02/01/23
- Adial enters into option agreement for sale of Purnovate assets to Adenomed
- 09/26/22
- Adial Pharmaceuticals announces in vivo data for Purnovate's PNV-5030
- 09/06/22
- Adial announces Purnovate achieved positive in-vivo data from its study
- 08/22/22
- Adial Pharmaceuticals appoints Cary Claiborne CEO
- 09/27/22 Stifel
- Equillium data sets stage for fuller update by mid-2023, says Stifel
- 09/27/22 Cantor Fitzgerald
- Equillium reports 'encouraging' early efficacy in LN, says Cantor Fitzgerald
- 09/27/22 H.C. Wainwright
- Equillium price target raised to $20 from $15 at H.C. Wainwright
- 03/24/22 H.C. Wainwright
- Equillium price target raised to $15 from $12 at H.C. Wainwright
- 02/01/23 Jefferies
- Evelo double downgraded at Jefferies after atopic dermatitis cohorts fail
- 02/01/23 Jefferies
- Evelo Biosciences downgraded to Underperform from Buy at Jefferies
- 11/16/22 Chardan
- Evelo Biosciences downgraded to Neutral from Buy at Chardan
- 08/15/22 Chardan
- Evelo Biosciences price target lowered to $5 from $12 at Chardan
ADIL Adial Pharmaceuticals - 08/17/22 Maxim
- Maxim cuts Adial Pharma to Hold on likely need for capital after AD04 miss
- 08/17/22 Maxim
- Adial Pharmaceuticals downgraded to Hold from Buy at Maxim
- 07/21/22 Maxim
- Adial Pharmaceuticals price target lowered to $3 from $5 at Maxim
- 11/14/22
- Evelo Biosciences reports Q3 EPS (28c), consensus (33c)
- 08/11/22
- Evelo Biosciences reports Q2 EPS (40c), consensus (43c)
- 11/14/22
- Equillium reports Q3 EPS (40c), consensus (15c)
- 08/15/22
- Equillium reports Q2 EPS (41c), consensus (41c)
ADIL Adial Pharmaceuticals - 11/14/22
- Adial Pharmaceuticals reports Q3 EPS (12c), consensus (18c)
- 08/16/22
- Adial Pharmaceuticals reports Q2 EPS (16c) vs. (25c) last year
- 02/01/23
- Fly Intel: After-Hours Movers
- 01/06/23
- Biotech Alert: Searches spiking for these stocks today
- 11/18/22
- Biotech Alert: Searches spiking for these stocks today
- 11/07/22
- Biotech Alert: Searches spiking for these stocks today
|
Hot Stocks
|
Equillium announced that… Equillium announced that an abstract was accepted for oral presentation at the Transplantation & Cellular Therapy Meetings of the American Society of Transplantation and Cellular Therapy, ASTCT, and the Center for International Blood & Marrow Transplant Research, CIBMTR. The Hybrid meetings will take place virtually and in person at the Orlando World Center Marriott, Orlando, Florida, February 15 - 19, 2023. The abstract highlights positive final study results, including long-term follow-up data for up to one year, from EQUATE, a Phase 1b study of itolizumab in combination with corticosteroids to treat subjects with newly diagnosed severe acute graft-versus-host disease. The data demonstrate promising outcomes in subjects with severe aGVHD, and Equillium has since initiated EQUATOR, a Phase 3 study of itolizumab as a potential initial therapy for aGVHD in combination with CS. ShowHide Related Items >><< - 12/23/22
- Equillium, Metracrine mutually agree to terminate merger agreement
- 12/16/22
- Equillium, Biocon initiate itolizumab study
- 12/08/22
- BML takes 15% stake in Metracrine, plans to vote against merger
- 12/06/22
- Equillium, Ono enter exclusive itolizumab option and asset purchase pact
- 09/27/22 Stifel
- Equillium data sets stage for fuller update by mid-2023, says Stifel
- 09/27/22 Cantor Fitzgerald
- Equillium reports 'encouraging' early efficacy in LN, says Cantor Fitzgerald
- 09/27/22 H.C. Wainwright
- Equillium price target raised to $20 from $15 at H.C. Wainwright
- 03/24/22 H.C. Wainwright
- Equillium price target raised to $15 from $12 at H.C. Wainwright
- 11/14/22
- Equillium reports Q3 EPS (40c), consensus (15c)
- 08/15/22
- Equillium reports Q2 EPS (41c), consensus (41c)
|
Syndicate
| ShowHide Related Items >><< - 12/23/22
- Equillium, Metracrine mutually agree to terminate merger agreement
- 12/16/22
- Equillium, Biocon initiate itolizumab study
- 12/08/22
- BML takes 15% stake in Metracrine, plans to vote against merger
- 12/06/22
- Equillium, Ono enter exclusive itolizumab option and asset purchase pact
- 09/27/22 Stifel
- Equillium data sets stage for fuller update by mid-2023, says Stifel
- 09/27/22 Cantor Fitzgerald
- Equillium reports 'encouraging' early efficacy in LN, says Cantor Fitzgerald
- 09/27/22 H.C. Wainwright
- Equillium price target raised to $20 from $15 at H.C. Wainwright
- 03/24/22 H.C. Wainwright
- Equillium price target raised to $15 from $12 at H.C. Wainwright
- 11/14/22
- Equillium reports Q3 EPS (40c), consensus (15c)
- 08/15/22
- Equillium reports Q2 EPS (41c), consensus (41c)
|
Hot Stocks
|
Equillium (EQ) and… Equillium (EQ) and Metacrine (MTCR) announced the mutual termination of their previously announced definitive merger agreement. "Equillium first set out to acquire Metacrine in an all-stock transaction in early 2022, with the intent of adding cash runway in a very difficult financing market," said Bruce Steel, CEO of Equillium. "However, our recent strategic partnership with Ono Pharmaceutical is expected to extend our cash runway into 2025, and possibly further with potential option exercise and milestone payments. We therefore find ourselves in a strong financial position, and with our pipeline of wholly-owned multi-cytokine inhibitors in the clinic we are excited about the opportunity to unlock value in our programs during 2023 and beyond." ShowHide Related Items >><< - 12/23/22
- Metacrine trading halted, news pending
- 09/06/22
- Metacrine trading resumes
- 09/06/22
- Equillium to acquire Metacrine in all-stock transaction
- 12/16/22
- Equillium, Biocon initiate itolizumab study
- 12/08/22
- BML takes 15% stake in Metracrine, plans to vote against merger
- 12/06/22
- Equillium, Ono enter exclusive itolizumab option and asset purchase pact
- 11/10/22
- Equillium initiates EQ101 open-label study
- 09/27/22 Stifel
- Equillium data sets stage for fuller update by mid-2023, says Stifel
- 09/27/22 Cantor Fitzgerald
- Equillium reports 'encouraging' early efficacy in LN, says Cantor Fitzgerald
- 09/27/22 H.C. Wainwright
- Equillium price target raised to $20 from $15 at H.C. Wainwright
- 03/24/22 H.C. Wainwright
- Equillium price target raised to $15 from $12 at H.C. Wainwright
- 12/29/21 Jefferies
- Metracrine assumed with a Hold at Jefferies
- 12/27/21 H.C. Wainwright
- Metracrine CMO exit 'not a big surprise,' says H.C. Wainwright
- 11/14/22
- Equillium reports Q3 EPS (40c), consensus (15c)
- 08/15/22
- Equillium reports Q2 EPS (41c), consensus (41c)
- 09/06/22
- Fly Intel: After-Hours Movers
|
Hot Stocks
|
Equillium announced that… Equillium announced that Biocon, in collaboration with Equillium, has initiated a Phase 2 clinical study of itolizumab in patients with ulcerative colitis, or UC. The Phase 2 double-blinded placebo-controlled clinical study is evaluating the safety and efficacy of itolizumab for biologics-naive patients with moderate to severe active UC, where patients are randomized 1:1:1 to receive a fixed dose of 140 mg of itolizumab, adalimumab, or placebo every two weeks for a 12-week treatment period, with adalimumab non-responders able to cross over to itolizumab. The study is expected to enroll up to 90 patients in multiple clinical trial sites in India. The trial design and initiation have been a collaborative effort, with help from the gastroenterologist community and leading global clinical and scientific experts in the field of inflammatory bowel disease, or IBD. ShowHide Related Items >><< - 12/08/22
- BML takes 15% stake in Metracrine, plans to vote against merger
- 12/06/22
- Equillium, Ono enter exclusive itolizumab option and asset purchase pact
- 11/10/22
- Equillium initiates EQ101 open-label study
- 11/02/22
- Equillium initiates EQ102 study
- 09/27/22 Stifel
- Equillium data sets stage for fuller update by mid-2023, says Stifel
- 09/27/22 Cantor Fitzgerald
- Equillium reports 'encouraging' early efficacy in LN, says Cantor Fitzgerald
- 09/27/22 H.C. Wainwright
- Equillium price target raised to $20 from $15 at H.C. Wainwright
- 03/24/22 H.C. Wainwright
- Equillium price target raised to $15 from $12 at H.C. Wainwright
- 11/14/22
- Equillium reports Q3 EPS (40c), consensus (15c)
- 08/15/22
- Equillium reports Q2 EPS (41c), consensus (41c)
|
Hot Stocks
|
Braden Leonard's BML… Braden Leonard's BML Investment Partners disclosed a 15.2% stake in Metracrine (MTCR), which represents over 6.4M shares. The filing with the SEC allows for activism. BML said it plans to vote against the company's proposed merger with Equillium (EQ) "unless the collar is adjusted to reflect the current Equillium share price." ShowHide Related Items >><< - 09/06/22
- Metacrine trading resumes
- 09/06/22
- Equillium to acquire Metacrine in all-stock transaction
- 09/06/22
- Metacrine trading halted, news dissemination
- 09/06/22
- Equillium to acquire Metacrine in all-stock transaction
- 12/06/22
- Equillium, Ono enter exclusive itolizumab option and asset purchase pact
- 11/10/22
- Equillium initiates EQ101 open-label study
- 11/02/22
- Equillium initiates EQ102 study
- 09/27/22
- Equillium gives data on the EQUALISE study evaluating itolizumab for LN
- 12/29/21 Jefferies
- Metracrine assumed with a Hold at Jefferies
- 12/27/21 H.C. Wainwright
- Metracrine CMO exit 'not a big surprise,' says H.C. Wainwright
- 09/27/22 Stifel
- Equillium data sets stage for fuller update by mid-2023, says Stifel
- 09/27/22 Cantor Fitzgerald
- Equillium reports 'encouraging' early efficacy in LN, says Cantor Fitzgerald
- 09/27/22 H.C. Wainwright
- Equillium price target raised to $20 from $15 at H.C. Wainwright
- 03/24/22 H.C. Wainwright
- Equillium price target raised to $15 from $12 at H.C. Wainwright
- 11/14/22
- Equillium reports Q3 EPS (40c), consensus (15c)
- 08/15/22
- Equillium reports Q2 EPS (41c), consensus (41c)
- 09/06/22
- Fly Intel: After-Hours Movers
|
Hot Stocks
|
Equillium and Ono… Equillium and Ono Pharmaceutical announced an option and asset purchase agreement through which Ono gains the exclusive option to purchase Equillium's rights to itolizumab, a first-in-class monoclonal antibody targeting CD6. These rights include all therapeutic indications and the rights to commercialize itolizumab in the United States, Canada, Australia, and New Zealand. Under the terms of the agreement, Equillium will receive a non-refundable upfront payment of approximately $26M and will also be eligible to receive up to an aggregate of approximately $138.5M for exercise of the option and milestone payments from development through first commercial sale. Equillium will be responsible for the conduct of all research and development of itolizumab, which will be fully funded by Ono on a quarterly basis commencing July 1 through the option period. The option period will expire three months following delivery of topline data from the EQUALISE study in lupus nephritis and interim data from the EQUATOR Phase 3 study in acute GVHD. ShowHide Related Items >><< - 11/10/22
- Equillium initiates EQ101 open-label study
- 11/02/22
- Equillium initiates EQ102 study
- 09/27/22
- Equillium gives data on the EQUALISE study evaluating itolizumab for LN
- 09/06/22
- Equillium to acquire Metacrine in all-stock transaction
- 09/27/22 Stifel
- Equillium data sets stage for fuller update by mid-2023, says Stifel
- 09/27/22 Cantor Fitzgerald
- Equillium reports 'encouraging' early efficacy in LN, says Cantor Fitzgerald
- 09/27/22 H.C. Wainwright
- Equillium price target raised to $20 from $15 at H.C. Wainwright
- 03/24/22 H.C. Wainwright
- Equillium price target raised to $15 from $12 at H.C. Wainwright
- 11/14/22
- Equillium reports Q3 EPS (40c), consensus (15c)
- 08/15/22
- Equillium reports Q2 EPS (41c), consensus (41c)
|
Earnings
|
Reports cash, cash… Reports cash, cash equivalents and short-term investments totaled $44.5M as of September 30, compared to $57.6M as of June 30, 2022. Equillium believes that its cash and investments, together with the additional cash that will be acquired with the expected closing of the Metacrine acquisition, will be sufficient to fund its operations into 2024. "I am proud of what our team has accomplished in the third quarter, including executing a definitive agreement to acquire Metacrine and announcing interim data from the Type B portion of the EQUALISE study in lupus nephritis. Since then, we have also initiated two new studies - a Phase 2 study of EQ101 in subjects with alopecia areata, and a Phase 1 study of EQ102 that will be positioned to treat patients with celiac disease. The Metacrine acquisition will meaningfully strengthen our cash position, which at closing is expected to add approximately $35 million to the balance sheet and extend our cash runway into 2024, taking us through multiple data catalysts from three different clinical programs over the next year," said Bruce Steel, CEO at Equillium. ShowHide Related Items >><< - 11/10/22
- Equillium initiates EQ101 open-label study
- 11/02/22
- Equillium initiates EQ102 study
- 09/27/22
- Equillium gives data on the EQUALISE study evaluating itolizumab for LN
- 09/06/22
- Equillium to acquire Metacrine in all-stock transaction
- 09/27/22 Stifel
- Equillium data sets stage for fuller update by mid-2023, says Stifel
- 09/27/22 Cantor Fitzgerald
- Equillium reports 'encouraging' early efficacy in LN, says Cantor Fitzgerald
- 09/27/22 H.C. Wainwright
- Equillium price target raised to $20 from $15 at H.C. Wainwright
- 03/24/22 H.C. Wainwright
- Equillium price target raised to $15 from $12 at H.C. Wainwright
- 08/15/22
- Equillium reports Q2 EPS (41c), consensus (41c)
|